Resistance to chemotherapy remains a major obstacle for the effective treatment of oral squamous cell carcinoma (OSCC). Evidence for the involvement of exosomes as important regulators of cisplatin chemoresistance in OSCC is still poorly understood. Our objective of this study was to explore the roles for exosomes in modulating key cellular pathways mediating response to chemotherapy. We first developed the cisplatin-resistant cell lines (HSC-3-R and SCC-9-R) and found that the conditioned media from cisplatin-resistant OSCC cells enhanced the chemoresistance of parental OSCC cell. The release of exosomes was blocked by inhibitor (GW4869) and exosomes were found to be involved in the chemoresistance of parental OSCC cell transferred from resistant cells. The exosomes derived from resistant cells and parental cells were isolated. Then, the isolated exosomes were characterized and quantified by electron microscopy, qNano analysis, and western blot analysis. Exosomes derived from cisplatin-resistant OSCC cells were found to enhance the chemoresistance of OSCC cell and decrease the DNA damage signaling in response to cisplatin. It was also found that exosomes derived from cisplatin-resistant OSCC cells transferred miR-21 to OSCC parental cells and induced cisplatin resistance by targeting phosphatase and tensin homolog and programmed cell death 4. Furthermore, the roles of cisplatin-resistant OSCC cells-derived exosomes in vivo were confirmed by subcutaneous xenograft mouse model. Collectively, the results suggest that exosomes released from cisplatin-resistant OSCC cells transmit miR-21 to induce cisplatin resistance of OSCC cells.
Introduction
Oral squamous cell carcinoma (OSCC) is the major head and neck cancer [1] . It is estimated that there are 300,000 cases per year around the world. The characteristics of OSCC are high degree of local invasion and high rate of metastasis to the cervical lymph nodes [2, 3] . Chemotherapy is the most common treatment for OSCC, which brings many benefits for patients with advanced cancers, including diminution of tumorsize, reduction of distant metastasis, and improved prognosis [4, 5] . However, resistance to anticancer agents is a major obstacle for the effectiveness of chemotherapy for OSCC and leads to the failure of chemotherapy [6] . Cisplatin is the first-generation anticancer compound and commonly used as the first-line chemotherapeutic regimen to treat OSCC. The use of cisplatin in the chemotherapy for OSCC often fails because of the rapid development of both inherent and acquired chemoresistance, which limits its application [7] . The cellular defense mechanisms of cisplatin resistance include multiple progresses, such as increasing drug detoxification, changes in DNA repair and cell cycle checkpoints, and reduced cell apoptosis [8] . Traditionally, most studies only focused on the molecular genetic basis of sensitivity and resistance to chemotherapy in cultured resistant cancer cells, the interaction between cisplatin-resistant OSCC cells and parental cells remain largely unknown. Therefore, a deeper understanding of molecular mechanisms is necessary.
Exosomes are small, nano-sized, lipid bilayer membrane vesicles with 30-150 nm in diameter that are released upon fusion of multi vesicular bodies with plasma membranes from diverse types of cells [9, 10] . Studies have shown that exosomes play key roles in cancer, including tumorigenesis, growth, angiogenesis, metastasis, immunosuppression, and drug resistance [11] [12] [13] . As mediators of intercellular communication, exosomes contain a wide range of functional proteins and genetic cargo, like mRNAs, miRNAs, and lncRNAs, that play an important role in exchanging genetic information and reprogramming of the recipient cells [14, 15] . Growing evidence indicates that exosomes act between heterogeneous populations of tumor cells, leading to a transmitted drug resistance in several types of tumors [16] [17] [18] . Exosomes have been shown to transmit drug resistance through delivering miRNAs [17, 19] . miRNAs are a class of short (19-24 nt) , non-coding RNAs molecules that post-transcriptionally regulate the translation and stability of mRNAs in multicellular organisms to control gene expression [20] . miRNAs function as tumor suppressors or oncogenes and have been shown to regulate cell differentiation, proliferation and apoptosis, and contribute to the development of tumors [21, 22] . MiR-21 has been found to be involved in the resistance to a variety of chemotherapeutic agents in both solid and hematologic tumors [23] [24] [25] [26] . Although the miRNA signatures of tumor-derived exosomes have been identified and studied in many types of tumors, exosomal miRNA signatures derived from cisplatin-resistant cancer cells have not been fully investigated and remain to be elucidated.
In this study, the cisplatin-resistant OSCC cell lines (HSC-3-R and SCC-9-R) were developed and the conditioned media from cisplatin-resistant OSCC cells were used to investigate whether it could enhance the chemoresistance of parental OSCC cell. It was found that exosomes are involved in the chemoresistance of parental OSCC cell transferred from resistant cells. Exosomes derived from cisplatin-resistant OSCC cells could transfer miR-21 to OSCC parental cells and induced cisplatin resistance by targeting phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4). In addition, a subcutaneous xenograft mouse model was established to confirm the roles of cisplatin-resistant OSCC cellderived exosomes in vivo.
Materials and Methods

Cell culture and induction of cisplatin resistance in OSCC cells
Human colorectal adenocarcinoma cell lines (HSC-3 and SCC-9) were obtained from American Type Culture Collection (Manassas, USA) and were cultured in DMEM medium (Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, USA). Cells were maintained at 37°C in a water-saturated atmosphere with 5% CO2. Cisplatin was purchased from SigmaAldrich (St Louise, USA) and dissolved in PBS. The cisplatinresistant HSC-3-R and SCC-9-R were developed from their parental cell line HSC-3 and SCC-9, respectively, according to the previously described methods [27] . Briefly, the HSC-3 and the SCC-9 were treated by gradually increasing doses of cisplatin in cell culture medium in subsequent passages for~6-8 months. Then, HSC-3-R and SCC-9-R cells were maintained in the presence of cisplatin (5 μM) in culture medium for 48 h in every alternate passage. All the resistant cells were cultured in the same condition as parental OSCC cell lines.
Cell viability assay
Cells were seeded into each well (3000 cell/well) in 96-well plates and subject to different treatment. At the end of treatment, the medium was removed and 90 μl of fresh medium were added to each well. Then, 10 μl of CCK-8 solution (Dojindo, Gaithersburg, USA) was added into each well and incubated for 2 h at 37°C. The absorbance was measured at 450 nm using the SpectraMax M5 microplate reader (Molecular Devices, Waltham, USA).
Apoptosis assay
Annexin V-FITC/PI staining was used to evaluate the cell apoptosis. After different treatment, cells were collected and double stained with Annexin V-FITC/PI (Annexin V-FITC Apoptosis Detection kit; BD Bioscience, San Jose, USA) according to the manufacturer's instructions. Then, the cells were analyzed by an EPICS XL-MCLFAC Scan (Becton-Dickinson, Mountain View, USA).
Isolation of exosomes
Cells were washed with PBS and incubated with freshly prepared complete medium containing exosome-free FBS for 48 h. Exosomes were isolated from the conditioned medium by differential centrifugation. Briefly, conditioned medium was centrifuged at 300 g for 10 min and then at 2000 g for 20 min to remove cells. Exosomes were pelleted by ultracentrifugation at 100,000 g for 90 min. They were resuspended in PBS and collected by ultracentrifugation again at 100,000 g for 90 min. Then, the isolated exosomes were quantified by qNano (Izon Science, Christchurch, New Zealand) and scanning electron microscopy. Cells were treated with GW4869 (10 μM) for 48 h to block the release of exosome.
Transmission electron microscopy
The isolated exosomes were prepared by mixing them with an equal volume of 4% paraformaldehyde (PFA). Then, exosomes were loaded on to a carbon-coated electron microscopy grid and examined by scanning electron microscopy. Samples were criticalpoint dried, mounted on specimen stubs, sputter-coated, and visualized using a Hitachi S3400 scanning electron microscope (Hitachi, Tokyo, Japan).
Quantitative real-time PCR
For exosomal miR-21 expression analysis, total RNA was extracted from exosomes using Trizol reagent (Invitrogen). Total RNA (1 μg) was first reverse transcribed using the QuantiMir RT kit (System Biosciences, Camarillo, USA). Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was performed using iTaq Universal SYBR green super mix (BioRad Laboratories Inc., Hercules, USA) on Applied Biosystems (Foster City, USA) step-one plus sequence detection system (Applied Biosystems). The relative expression of exosomal miR-21 was normalized to cel-miR-39.
For cellular mRNA and miR-21 expression analysis, total RNA was extracted from cells using Trizol reagent (Invitrogen). One microgram of RNA was used as the template for single strand cDNA synthesis using random primers and ImProm-II Reverse Transcription System (Promega, Madison, USA) according to the manufacturer's instructions. qRT-PCR was performed for PTEN, PDCD4, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), miR-21, and U6. The cDNA was amplified by an Applied Biosystems step-one plus sequence detection system (Applied Biosystems). The relative expression was normalized to endogenous controls using the comparative cycle threshold (CT) method and fold change was calculated as 2 −ΔΔ Ct in gene expression. The mRNA was normalized to GAPDH and miRNA was normalized to U6. The primers used were as follows: PDCD4 forward primer, 5′-GGCCTCCAAGGA-GTAAGACC-3′; PDCD4 reverse primer, 5′-AGGGGTCTACATGGCAACTG-3′; GAPDH forward primer, 5′-AAGGGAAGGTTGCTGGATAGG-3′; GAPDH reverse primer, 5′-CACATCCACCTCCTCCACATC-3′.
Western blot analysis
Cells and exosomes were homogenized in RIPA lysis buffer [50 mM Tris-Cl pH 8.0, 150 mM NaCl, 0.02% NaN 3 , 0.1% sodium dodecyl sulfate (SDS), 100 μg/ml phenylmethylsufonyl fluoride, 1 μg/ml Aprotinin, and 1% Triton]. After centrifugation, cell lysates (100 μg/ lane) were subject to 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, USA). Western blot analysis was performed according standard procedures. The primary antibodies used were anti-PTEN (1:1000; Santa Cruz, Santa Cruz, USA), anti-PDCD4 (1:1000; Cell Signaling Technology, Beverly, USA), anti-GAPDH (1:1000; CST), anti-γH2AX (1:2000; CST), anti-CD63 (1:1,000; Millipore), and anti-CD81 (1:1000; CST) antibodies. The secondary antibody used was horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:1000; Promab, Richmond, USA).
Cell transfection
The pre-miR-21 (miRNA mimic), pre-control (scrambled negative controls), antisense miR-21 (inhibitor), and anti-control were designed and synthesized by RiboBio (Guangzhou, China). The HSC-3 cells were transfected with the aforementioned pre-miR-21, pre-control, antisense miR-21, and anti-control for 48 h using Lipofectamine 3000 (Invitrogen) following the manufacturer's protocol. Cells were harvested after 48 h for qRT-PCR to assess the efficiency of knockdown and overexpression.
Labeling of exosomes
Exosomes were pre-labeled with CM-DiI (Invitrogen) according to the manufacturer's instructions and then washed with PBS and centrifuged at 110,000 g for 70 min to remove the excess dye. Cells were grown in wells of 24-well plates and then incubated with labeled exosomes (10 μg/ml) for 4 h. The cells were then washed three times with PBS, fixed with 4% PFA for 10 min.
Xenograft tumor model
All animal procedures were approved by national guidelines the Animal Care Ethics Committee of Tongchuan People's Hospital. Twelve male BALB/c nu/nu mice (5-6 weeks) were purchased from the Laboratory Animal Center of Shanghai, Academy of Science (Shanghai, China). All mice received subcutaneous injections of HSC-3 cells in the right armpit (5 × 10 6 cells in 100 μl PBS per mouse). When the tumors reached a volume of 50-100 mm 3 , 12 mice were randomly divided into two groups (cisplatin+exo-HSC-3 and cisplatin+exo-HSC-3-R). All mice were intraperitoneally injected with cisplatin (4 mg/kg,) once a day for 4 days. The exosome derived from HSC-3 and HSC-3-R cells were subcutaneously injected (100 μg total protein in 100 μl, in the vicinity of the subcutaneous tumors), respectively. The tumor volume was measured with a caliper every 5 days.
Immunohistochemistry
Tissue samples were cut into 4-μm-thick sections and fixed in 10% formalin, dehydrated and then embedded in paraffin. Slides were baked, deparaffinized in xylene, passed through graded alcohols, and then antigen-retrieved with 1 mM ethylenediaminetetraacetic acid, pH 8.0 (Invitrogen). Endogenous peroxidase was blocked with 3% peroxide for 5 min. Slides were blocked using normal goat serum and subsequently incubated with anti-PTEN (Santa Cruz) and anti-PDCD4 (CST) primary antibodies at 1:400 dilution. Slides were washed and treated with Signal stain boost IHC detection reagent (HRP, rabbit, CST). Staining development was achieved by incubation with DAB and DAB Enhancer. Slides were counterstained with hematoxylin.
Statistical analysis
All results are presented as the mean ± standard error of mean (SEM) of at least three independent experiments. Student's t-test was used to assess differences between two groups, and one-way analysis of variance was used for multiple comparisons. A value of P < 0.05 was considered to be statistically significant.
Results
Conditioned media from cisplatin-resistant OSCC cells enhanced the chemoresistance of OSCC cell
Cisplatin-resistant cell lines, HSC-3-R and SCC-9-R were developed by treatment with increasing doses of cisplatin in successive passages for 6 months from their parental cell line, HSC-3 and SCC-9, and then maintained in the presence of 3 μM cisplatin. The conditioned media from cisplatin-resistant OSCC cells were collected and used to culture the corresponding parental cells for 48 h. Then, the treated cell lines were exposed to various concentrations of cisplatin to determine the cisplatin-induced-cytotoxicity. The viability profile of the parental cells (HSC-3 and SCC-9) cultured with conditioned media from cisplatin-resistant OSCC cells were assessed. As shown in Fig. 1A , the HSC-3 cell cultured with HSC-3-R-conditioned media had a significantly higher survival than HSC-3-conditioned media. Similar result was found in SCC-9 cell cultured in SCC-conditioned media (Fig. 1B) . To assess whether the exosomes secreted by cisplatin-resistant OSCC cells were involved in the chemoresistance of OSCC cells, GW4869 (an inhibitor of exosomes release) was used to block the exosome secretion in HSC-3-R and SCC-9-R cells. The conditioned media were collected after GW4869 treatment and used to culture the corresponding parental cells for 48 h. The treatment of GW4869 had no effect on the cell viability of OSCC cells (Fig. 1C) . Then, the treated cell lines were also exposed to various concentrations of cisplatin for 24 h to determine the cisplatininduced-cytotoxicity. The cell viability was decreased by exosomedepleted conditioned media, and conditioned media without exosomes deleption from cisplatin-resistant OSCC cells increased the cell viability (Fig. 1A,B) . The HSC-3 and SCC-9 cells treated with conditioned media from their corresponding cisplatin-resistant cells showed less cell apoptosis induced by cisplatin (Fig. 1D,E) . In addition, the exosome-depleted conditioned media from exosomeblocked HSC-3-R and SCC-9-R cells increased the cell apoptosis compared with conditioned media from cisplatin-resistant HSC-3-R and SCC-9-R cells. Cisplatin causes DNA crosslinking and stimulates H2AX phosphorylation at Serine 139 to generate γH2AX as a major marker for DNA damage signaling in response to DNA double-strand break [28] . Cisplatin-triggered γH2AX in HSC-3 and SCC-9 cells after treatment with different conditioned media was assessed. Conditioned media from cisplatin-resistant OSCC cells decreased the protein level of γH2AX induced by cisplatin, while exosome-depleted conditioned media restored the effect, indicating that conditioned media from cisplatin-resistant OSCC cells decreased the cisplatin-induced DNA damage by exosomes in conditioned media (Fig. 1F,G) . In addition, exosomes from cisplatin-resistant cell lines Figure 1 . Conditioned media from cisplatin-resistant OSCC cells enhanced the chemoresistance of OSCC cell (A and B) Cisplatin-resistant cell lines (HSC-3-R and SCC-9-R) were developed from their parental cell line (HSC-3 and SCC-9). The conditioned media from cisplatin-resistant cells under GW4869 treatment or not and parental cell line were collected and used to culture the corresponding parental cells for 48 h. The conditioned media from parental cell line (HSC-3 and SCC-9) cultured with the exosomes from cisplatin-resistant cell lines (HSC-3-R and SCC-9-R), respectively. Then, the conditioned media-treated cells were exposed to various concentrations (0-20 μM) of cisplatin for 24 h to determine the cisplatin-induced-cytotoxicity. The conditioned media from parental cell line (HSC-3 and SCC-9) were used as control. The cell viability of parental cells (HSC-3 and SCC-9) cultured with different conditioned media under cisplatin treatment was assessed by CCK-8. (C) Cells were treated with GW4869 for 48 h, and the cell viability was assessed by CCK-8 assay. The treatment of GW4869 had no effect on the cell viability of OSCC cells. (D) Flow cytometry was used to evaluate the cell apoptosis of parental cells (HSC-3 and SCC-9) cultured with different conditioned media under cisplatin treatment for 48 h. (E) Hoechst staining of HSC-3 cells cultured with different conditioned media under cisplatin treatment for 48 h. (F and G) The conditioned media-treated cells were exposed to cisplatin for 48 h. Western blot analysis of the protein expression of γH2AX in HSC-3 and SCC-9 cells. Data represent three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001. ns, no significant.
were found to decrease the protein level of γH2AX. DNA damage induced by cisplatin was decreased by exosomes from cisplatinresistant cell lines (Fig. 1F,G) .
Exosomes derived from cisplatin-resistant OSCC cells enhanced the chemoresistance of OSCC cell
To further confirm whether the exosomes secreted by cisplatinresistant OSCC cells were involved in the chemoresistance of OSCC cells, exosomes were initially purified from the conditioned medium of cisplatin-resistant cells and parental cells. The purified exosomes were examined by electron microscopy ( Fig. 2A) . The particle diameter of the population of small vesicles collected from conditioned medium was quantified using qNano analysis and showed typical rounded particles ranging from 30 to 160 nm in diameter (Fig. 2B) . The expression of exosomal markers CD63 and CD81 was further quantified by western blot analysis (Fig. 2C) .
The cisplatin-resistant OSCC cell-derived exosomes were labeled with fluorescent CM-Dil. The labeled exosomes were internalized by OSCC cells after 2 h incubation and detected by fluorescence microscopy (Fig. 2D) . The HSC-3 cells were incubated with exosomes derived from HSC-3-R or HSC-3 cells, and then exposed to various concentrations of cisplatin. The cells incubated with exosomes derived from HSC-3-R cells had a significantly higher survival than cells incubated with exosomes derived from HSC-3 cells. A parallel result was obtained in HSC-3 cells incubated with exosomes derived from SCC-9-R cells (Fig. 2E) . A decreased cell apoptosis was also found in parental cells incubated with exosomes derived from HSC-3-R cells under the treatment of cisplatin (Fig. 2F) . In addition, exosomes derived from cisplatin-resistant OSCC cells decreased the protein level of γH2AX induced by cisplatin, indicating that the DNA damage induced by cisplatin was inhibited by exosomes derived from cisplatin-resistant OSCC cells (Fig. 2G) . The HSC-3 cells were incubated with exosomes derived from HSC-3-R or HSC-3 cells and then exposed to various concentrations of cisplatin. The SCC-9 cells were incubated with exosomes derived from SCC-9-R or SCC-9 cells and then exposed to various concentrations of cisplatin. After 24 h of treatment with cisplatin, cell viability of parental cells (HSC-3 and SCC-9) cultured with different exosomes was assessed by CCK-8. (F) The HSC-3 and SCC-9 cells were incubated with exosomes derived from HSC-3-R or HSC-3 cells and then exposed to cisplatin for 48 h. Cell apoptosis was analyzed by flow cytometry. (G) The HSC-3 cells were incubated with exosomes derived from SCC-9-R, SCC-9, HSC-3-R, or HSC-3 cells and the protein levels of γH2AX were analyzed by western blot analysis. All experiments were repeated three times. Data were presented as the mean ± SEM. *P < 0.05 and **P < 0.01.
miR-21 in the exosomes derived from cisplatinresistant OSCC cells induced cisplatin resistance by targeting PTEN and PDCD4
The miRNAs have been reported to be encapsulated in exosomes and transfer between living cells to mediate the cell-cell communication [29] . Growing evidence indicated that miR-21 is involved in chemoresistance in lung cancer, pancreatic cancer, OSCC, ovarian cancer, and gastric cancer [23, 24, [30] [31] [32] . miR-21 is highly expressed in the exosome derived from cancer-associated adipocytes of ovarian cancer and confers paclitaxel resistance in ovarian cancer cells [23] . Therefore, the miR-21 level was measured in exosomes derived from cisplatin-resistant OSCC cells (HSC-3-R and SCC-9-R) and their parental cells (HSC-3 and SCC-9). It was found that miR-21 was highly expressed in the exosome derived from HSC-3-R and SCC-9-R cells (Fig. 3A) . In addition, conditioned media from HSC-3-R cells and exosomes in conditioned media from HSC-3-R cells increased the miR-21 level in HSC-3 cells (Fig. 3B) . Intriguingly, the exosomes derived from HSC-3-R cells significantly increased the miR-21 level in HSC-3 cells, indicating that the cisplatin-resistant OSCC cells could transfer miR-21 to parental OSCC cells (Fig. 3C) . Then, miR-21-induced cisplatin resistance of OSCC cells was confirmed by transiently transfecting the synthetic miR-21 precursor, antisense miR-21 inhibitor, and negative control into HSC-3 cells (Fig. 3D) . PDCD4, a suppressor of tumorigenesis, was involved in the resistance to anticancer agents [26] . It has been reported that miR-21 enhances 5-fluorouracil resistance in human pancreatic The HSC-3 cells were incubated with exosomes derived from HSC-3-R or HSC-3 cells, and protein levels of PTEN and PDCD4 were analyzed. All experiments were repeated three times. Data were presented as the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
cancer cells by targeting PTEN and PDCD4 [24] . Therefore, we postulated that PTEN and PDCD4 might be the targets of miR-21 in HSC-3 cells. As shown in Fig. 3E -G, ectopic expression of miR-21 inhibited the mRNA and protein levels of PTEN and PDCD4 in HSC-3 cells, indicating that the expressions of PTEN and PDCD4 in HSC-3 cells were regulated by miR-21. In addition, the exosomes derived from HSC-3-R cells were found to decrease the mRNA and protein levels of PTEN and PDCD4 in HSC-3 cells compared with exosomes from HSC-3 cells (Fig. 3H,I ).
Cisplatin-resistant OSCC cell-derived exosomes induced cisplatin resistance in OSCC cells in vivo
To determine whether cisplatin-resistant OSCC cell-derived exosomes can induce cisplatin resistance in OSCC cells in vivo, we established a subcutaneous xenograft model in nude mice and injected cisplatin together with exosomes derived from HSC-3-R and HSC-3 cells into the mice. Exosomes derived from HSC-3-R promoted the growth of tumor and enhanced the cisplatin resistance in OSCC (Fig. 4A,B) . We stained the Ki-67 and found more Ki-67 positive cells in exosomes derived from HSC-3-R group (Fig. 4C) . The injection of exosomes derived from HSC-3-R cells significantly increased the miR-21 level (Fig. 4D) . Immunohistochemical analysis revealed that the protein levels of PTEN and PDCD4 were significantly decreased by injection of exosomes derived from HSC-3-R cells (Fig. 4E,F) . These results suggest that cisplatin-resistant OSCC cell-derived exosomes could induce cisplatin resistance in OSCC cells by up-regulating the miR-21 level and down-regulating the expression of PTEN and PDCD4 in vivo.
Discussion
The interaction between tumor cells and microenvironment is an important factor in cancer therapy. The tumor microenvironment composed of exosomes may mediate the communication of a tumor cell with the neighboring cell, and thus regulate the function of recipient cells [33] . Specific cell-derived exosomes can transfer multidrug resistance-associated proteins or RNAs to recipient cells. Increasing evidence implicates that exosomes can transfer drug resistance through delivering miRNAs. Previous studies have reported that cancer-associated fibroblasts cell-derived exosomes transfer miR-21 to confer ovarian cancer cells paclitaxel resistance in ovarian cancer cells [23] . The biological functions of miR-21 have been extensively investigated, and the high expression of miR-21 may be a characteristic of many type of cancer cells, and represent a common feature of pathological cell growth or cell stress [26] . It was reported that OSCCs released the exosome-transmitted miR-21 under hypoxic. The exosomes are transferred to the normoxic cells to modulate the bioactivity of normoxic cells [34] . In our study, the (F) Representative images of tumors with low PDCD4 expression. Scale bars, 100 μm. All experiments were repeated three times. Data were presented as the mean ± SEM. *P < 0.05 and **P < 0.01. exosomes derived from cisplatin-resistant OSCC cells were rich in miR-21 compared with exosomes derived from parental OSCC cells. Exosomes derived from cisplatin-resistant OSCC cells were found to enhance the chemoresistance of OSCC cell and reduce the DNA damage signaling in response to cisplatin.
In addition, miR-21 has been reported to counteract the expression of putative tumor-suppressive targets, such as PTEN and PDCD4. MiR-21 was reported to enhance 5-fluorouracil resistance in human pancreatic cancer cells by targeting PTEN and PDCD4 [24] . PDCD4 is a tumor suppressor gene involved in apoptosis, cell transformation, invasion, and tumor progression. PDCD4 exerts its activity by interacting with eIF4A and eIF4G to suppress mRNA translation and further inhibit the growth and proliferation of tumors. Knockdown of PDCD4 promoted the resistance to docetaxel in prostate cancer cells, and PDCD4 is a functional target for miR-21-induced chemoresistance to docetaxel [35] . PTEN, a known tumor suppressor gene, results in attenuation of PI3K/Akt/mTOR signaling pathway and tumor growth. Previous studies have reported that miR-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer [25] . In our study, we confirmed that PTEN and PDCD4 were the functional targets for miR-21 and involved in the cisplatin resistance in OSCC cells. Moreover, we also found that exosomes derived from cisplatin-resistant cells decreased both the mRNA and protein levels of PTEN and PDCD4 in HSC-3 cells compared with exosomes from HSC-3 cells. Furthermore, protein levels of PTEN and PDCD4 were significantly decreased by injection of exosomes derived from cisplatin-resistant cells in the subcutaneous xenograft model.
In summary, our results showed an intriguing possibility that exosomes released from cisplatin-resistant OSCC might transmit miR-21 to induce cisplatin resistance of OSCC cells by targeting PTEN and PDCD4. Recent studies have shown the diagnostic and prognostic value of miR-21. Further use of miR-21 as a biomarker and target for cancer treatments is likely to improve the outcome for patients with cancer.
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